Compare REXR’s preferred stocks (REXR.PR.B and REXR.PR.C) to top REIT investment-grade options trading below par. See competitive ratings and metrics.
1d
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and ...
FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval –– $12 Million Financing Strengthens ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsMarDee Haring-Layton - Chief Accounting ...
Objective To assess the effects of behaviourally informed short message service (SMS) reminders on demand for human ...
Q3 2025 Earnings Call Transcript November 12, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $0, expectations ...
Barton pivots toward commercialisation with $20m cash in bank HIGHLIGHTS $20m estimated cash balance after proceeds of recent $15m institutional placement and SPP Share Purchase Plan (SPP) opened 23 ...
Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including ...
Research and development (R&D) expenses for the three months ended September 30, 2025, were $5.3 million, compared to $6.0 million in the same three-month period of 2024 and a decrease from $6.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback